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Primary Mucoepidermoid Carcinoma of the Esophagus
Shaobin Chen, MD, Yuping Chen, MD, Jiesheng Yang, MD, Weiping Yang, MD, Hongrui Weng, MD,
Hua Li, MD, and Ditian Liu, MD
Introduction: Primary mucoepidermoid carcinoma (MEC) of the
esophagus is an uncommon neoplasm characterized by a diffuse
mixture of squamous and mucus-secreting glandular carcinoma
cells. Its biological behavior and response to therapies have not been
well studied. Surgical resection is still the primary treatment, but the
prognosis is poor. This retrospective study was designed to inves-
tigate the clinical characteristics, diagnosis, treatment, and prognosis
of primary esophageal MEC.
Methods: Clinical data were retrospectively analyzed from 36
patients with pathologically confirmed primary esophageal MEC
who underwent transthoracic esophagectomy with lymphadenec-
tomy between January 1991 and June 2010 at the Cancer Hospital of
Shantou University Medical College. There were 27 men and 9
women ranging in age from 40 to 78 years (median, 58 years).
Twenty-six of the 36 patients were treated with surgery alone. The
other 10 were treated with surgery plus postoperative radiotherapy.
The Kaplan-Meier and log-rank methods were used to estimate and
compare survival rates. Cox’s hazard regression model was used to
identify prognostic factors, with entry factors of gender, age (60
years versus60 years), length of the primary lesion (5 cm versus
5 cm), location of the primary lesion, macroscopic tumor type,
tumor cell differentiation, pT, pN, pTNM stage, operation type
(radical/palliative), and radiotherapy (yes/no).
Results: The clinical symptoms, radiological and endoscopic fea-
tures of primary esophageal MEC were similar to those of esopha-
geal squamous cell carcinoma (ESCC). Of the 20 cases who under-
went preoperative endoscopic biopsy, 18 cases were misdiagnosed
as ESCC and 2 were misdiagnosed as esophageal adenosquamous
carcinoma. The mean follow-up duration of this series was 38.8
months (range, 3–142 months). Twenty-two patients had died, 12
were still alive, and 2 were lost to follow-up. The median survival
time of the 36 patients was 29.0 months (95% confidence interval
20.0–38.0), and the 1-, 2-, 3-, and 5-year overall survival rates were
80.6%, 57.1%, 34.4%, and 25.8%, respectively. The 5-year survival
rate of 25.8% was lower than 5-year absolute survival rate of 39.2%
for ESCC patients who had undergone surgical resection during the
same period at our center. For patients who underwent a radical
operation, the 5-year survival rate of 32.0% for MEC patients was
also lower than that of 41.7% (908/2175) for ESCC patients. In
univariate analysis, pN (pN0/pN1–3) (p  0.003) and operation type
(radical/palliative) (p  0.006) significantly influenced the median
survival time of MEC patients. In multivariate analysis, pN (pN0/
pN1–3) (p  0.002) and operation type (radical/palliative) (p 
0.004) were independent prognostic factors.
Conclusions: Primary esophageal MEC is a rare disease and prone
to be misdiagnosed. Lymph node metastasis and operation are
independent prognostic factors. Surgical resection is the primary
treatment, but the prognosis is poor.
Key Words: Esophagus, Mucoepidermoid carcinoma, Treatment,
Prognosis.
(J Thorac Oncol. 2011;6: 1426–1431)
Primary mucoepidermoid carcinoma (MEC) of the esoph-agus is an uncommon malignant esophageal neoplasm
characterized by a diffuse mixture of squamous and mucus-
secreting glandular carcinoma cells.1–3 Its biological behavior
and response to therapies have not been well studied. This
report reviews the clinical characteristics, diagnosis, treat-
ment, and prognosis of 36 cases with primary esophageal
MEC who underwent esophagectomy in our hospital from
January 1991 to June 2010.
PATIENTS AND METHODS
A total of 4253 cases with esophageal carcinomas
underwent surgical resection in the Cancer Hospital of Shan-
tou University Medical College between January 1991 and
June 2010. In thirty-six cases (0.85%, 36/4253), the histolog-
ical diagnosis was primary esophageal MEC. The clinical
records of these 36 patients were analyzed retrospectively.
Patient Selection
All patients were questioned about their medical history
and underwent physical examinations. Chest radiograph, bar-
ium meal, contrast-enhanced computed tomography scan of
the chest, Doppler ultrasound examination of the abdomen,
complete blood count, blood biochemistry analyses, and liver
and renal function evaluations were also performed. Twenty
patients underwent esophagoscopic biopsy before surgery.
Unless clinically indicated, brain magnetic resonance imag-
ing and radioactive isotope bone scans were not performed.
All the specimens were examined and checked again by
expert pathologists.
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Patient Characteristics
This study group comprised 27 men and 9 women
ranging in age from 40 to 78 years (median, 58 years). The
primary lesions were most often found in the middle third of
the thoracic esophagus and had a median length of 5.0 cm
(3.0–5.0 cm). The macroscopic tumor type was classified as
medullary type in 27 cases, intraluminal in 1 case, mushroom
type in 1 case, ulcerative type in 2 cases, and sclerotic type in
5 cases. The clinical manifestations were identical to that of
other types of esophageal cancer, with dysphagia, retrosternal
pain, and loss of body weight being the main presenting
symptoms.
Based on the 2010 American Joint Committee on Can-
cer and International Union for Cancer Control tumor node
metastasis (TNM) staging system for esophageal adenocarci-
noma, the study included one stage Ia, 23 stage IIb, 6 stage
IIIa, 2 stage IIIb, and 4 stage IIIc patients.
None of the 36 patients underwent chemotherapy or
radiotherapy before surgery, and none had prior malignant
disease or distant metastases on routine examination before
surgery.
Treatment
All 36 patients underwent transthoracic esophagectomy
with two-field lymphadenectomy (the mediastinal and peri-
gastric lymph nodes), including 32 cases of radical excision
and 4 cases of palliative resection. A total of 378 lymph
nodes were removed, with 34 metastases. Eight of the 36
patients (22.2%) proved postoperatively to have histologi-
cally confirmed lymph node metastases. Postoperative com-
plications included one case of pneumonia, one case of
chylothorax, and one case of an esophagogastric anastomotic
leak. No patient died during treatment in hospital. No patient
died during the treatment in hospital.
Twenty-four patients who underwent a radical opera-
tion were treated with surgery alone, and eight radically
operated patients were treated with surgery plus postoperative
radiotherapy. Two of the four patients who underwent a
palliative operation were treated with surgery alone, and the
other two were treated with surgery plus postoperative radio-
therapy. Therapeutic radiation was delivered using 6 or 8 MV
photons. A total dose of 44 to 60 Gy (median, 50 Gy) was
delivered in 2 Gy fractions 5 days a week.
Statistical Analysis
The survival time was calculated from the start of
treatment to the point of death or last follow-up. SPSS 13.0
software (SPSS Inc., Chicago, IL) was used to analyze
prognostic factors by Cox’s hazard regression model, with
the entry factors of gender, age (60 years versus 60
years), length of the primary lesion (5 cm versus 5 cm),
location of the primary lesion, macroscopic tumor type,
tumor cell differentiation, pT, pN, pTNM stage, operation
(radical/palliative), and radiotherapy (yes/no). The cumula-
tive survival of the patients was calculated by the Kaplan-
Meier method. Survival curves were also plotted, and the
survival curves were tested by the log-rank method. p values
less than 0.05 were considered significant. The results of
treatment in this group of patients were compared with the
results in patients with ESCC treated during the same period.
RESULTS
The clinopathologic features of the 36 primary esoph-
ageal MEC patients are shown in Table 1.
The macroscopic appearance of MEC was indistin-
guishable from pure squamous cell carcinoma (SCC). Micro-
scopically, MEC was characterized by the presence of an
intimate mixture of squamous cells, mucus-secreting cells,
and “intermediate” cells in varying proportions (Figure 1).
Periodic Acid Schiff, alcian blue, and mucicarmine stains
were positive in the mucus and mucus-secreting cells. In the
squamous regions, there were intercellular bridges, individual
cell keratinization, and cancer pearl.
Twenty patients underwent esophagoscopic biopsy be-
fore surgery, but none of the histological specimens taken
were diagnosed as MEC. Eighteen cases were misdiagnosed
as SCC, and the other two were misdiagnosed as adenosqua-
mous carcinoma.
By June 2010, with a mean follow-up of 38.8 months
(3–142 months), 22 patients had died, 12 were still alive, and
2 were lost to follow-up.
The median survival time (MST) of the 36 patients was
29.0 months (95% confidence interval 20.0–38.0), and the 1-,
2-, 3-, and 5-year overall survival rates were 80.6%, 57.1%,
34.4%, and 25.8%, respectively (see Figure 2). One patient
died of pneumonia 3 months after the surgery.
Four thousand twenty-three of the 4253 esophageal
carcinoma patients were histologically diagnosed as SCC.
Based on the 2010 American Joint Committee on Cancer/
International Union for Cancer Control TNM staging system,
this group included 126 stage Ia, 179 stage Ib, 653 stage IIa,
1063 stage IIb, 950 stage IIIa, 405 stage IIIb, 611 stage IIIc,
and 36 stage IV patients (Table 2). The 5-year absolute
survival rate for ESCC patients was 39.2% (912/2328).
Finally, we assessed the relationship between the clin-
icopathologic features and the prognosis of the MEC patients.
The MST (95% confidence interval) at 48.0 months (6.9–
89.1) for cases without lymph node metastasis (pN0) was
longer than that of 23.0 months (17.3–28.7) for cases with
lymph node metastasis (pN1–3) (p  0.003; see Figure 3).
Furthermore, the MST was longer for cases that had under-
gone a radical operation (33.0 months) compared with a
palliative operation (11.0 months; p  0.006) (Figure 4).
Other recorded clinicopathologic features, including gender,
age (60 years versus 60 years), length of the primary
lesion (5 cm versus 5 cm), location of the primary lesion,
macroscopic tumor type, tumor cell differentiation, pT,
pTNM stage, and radiotherapy (yes/no), did not show a
statistically significant correlation with prognosis (p  0.05;
Table 3). In multivariate analysis, pN (p  0.002) and
operation type (p  0.004) were found to be independent
factors in the prediction of prognosis (Table 4). Patients who
did not have lymph node metastasis and had undergone
radical surgery had a relatively better survival.
Sixteen patients had complete recurrence and metasta-
sis data. The first failure sites in these 16 cases included
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locoregional recurrences in 8 cases, locoregional recurrences
with distant metastases in 2 cases, and distant metastases in 6
cases. The mean time from treatment to failure was 15.0
months (1–40 months). Metastasis was detected in the bone
in three cases, the liver in two cases, distant lymph nodes in
two cases, and the lung in one case.
DISCUSSION
MEC is a malignant tumor characterized by the pres-
ence of an intimate mixture of mucus, intermediate, and
epidermoid cells.4,5 It is the most common malignant neo-
plasm of the salivary glands, accounting for approximately
one-third of all salivary malignancies.6,7 Primary esophageal
MEC is relatively uncommon, accounting for less than 1% of
all cases of primary esophageal carcinoma.1,2 Most of these
patients are men and older than 50 years. The tumor is located
mainly at the middle and lower thirds of the esophagus.1,8 In
the current study, MEC accounted for 0.85% of all esopha-
geal carcinoma at our institution, with a median age of 58
years. Twenty-seven cases were men and 9 were women (sex
ratio  3:1). The primary lesions were mainly located at the
middle and lower third of the esophagus (86.1%).
The origin of primary esophageal MEC is still obscure.9
Most authors believe that this type of tumor arises from the
esophageal gland cells or ductal cells.3,10,11 Evidence in
support of this theory includes the submucosal location of
some of this tumor and the embryologically similar origin of
the esophageal and salivary glands. But there is also evidence
that hints at a squamous epithelial cell origin for this group of
tumors. First, the behavior of this tumor differs from that of
TABLE 1. Clinopathologic Features of the 36 Patients with Primary Esophageal MEC
Gender Age (yr) Location Length (cm)
Macroscopic
Tumor Type pT pN
Tumor Cell
Differentiation Treatment Result
Last
Follow-Up (mo)
M 60 Mt 5 Medullary 2 1 Moderate S D 26
M 56 Ut 7 Medullary 3 0 Moderate S D 23
M 45 Mt 15 Ulcerative 3 0 Moderate S D 33
M 67 Mt 4 Mushroom 3 0 Poor S D 14
M 65 Mt 3 Medullary 3 0 Moderate S D 26
M 47 Mt 5 Medullary 3 0 Moderate S  R D 11
M 52 Lt 8 Intraluminal 4 1 Well S D 16
M 51 Mt 4.5 Medullary 3 1 Moderate S D 13
F 62 Mt 4 Sclerotic 3 0 Poor S D 29
M 40 Mt 3.5 Medullary 3 0 Moderate S A 142
F 63 Lt 4 Sclerotic 3 0 Moderate S D 59
M 66 Ut 8 Medullary 4 0 Moderate S D 23
M 46 Mt 6 Medullary 3 0 Moderate S A 123
M 45 Mt 7 Medullary 4 1 Well S D 8
F 78 Mt 6 Medullary 4 0 Well S L 86
M 40 Ut 3 Medullary 3 0 Moderate S A 110
M 45 Lt 5 Medullary 3 1 Moderate S D 20
F 67 Mt 5 Medullary 3 0 Moderate S D 6
M 53 Mt 4 Medullary 3 0 Well S  R A 86
F 68 Mt 4 Medullary 3 0 Moderate S A 76
M 67 Mt 5 Medullary 3 0 Moderate S D 48
M 68 Ut 5 Medullary 4 0 Moderate S  R A 71
M 52 Mt 3.5 Sclerotic 4 0 Well S  R A 66
M 60 Mt 5 Medullary 3 0 Well S D 29
M 72 Mt 8 Medullary 4 0 Moderate S  R D 23
F 47 Mt 3 Medullary 3 0 Moderate S D 29
M 58 Mt 5 Medullary 3 0 Moderate S A 47
M 65 Mt 4 Medullary 3 0 Moderate S D 8
M 52 Mt 5 Ulcerative 3 0 Poor S  R L 6
F 47 Mt 4 Sclerotic 3 1 Moderate S  R D 18
F 63 Mt 5 Medullary 3 0 Well S A 35
M 41 Mt 3 Sclerotic 2 1 Poor S  R A 31
M 57 Mt 3 Medullary 3 0 Moderate S  R A 31
M 70 Ut 5.5 Medullary 1 0 Moderate S D1 3
M 55 Mt 5 Medullary 3 1 Poor S D 9
F 67 Mt 4 Medullary 3 0 Moderate S  R A 13
MEC, mucoepidermoid carcinoma; Ut, upper third of thoracic esophagus; Mt, middle third of thoracic esophagus; Lt, lower third of thoracic esophagus; S, surgery; R,
radiotherapy; A, alive; D, died of tumor recurrence; D1, died of nontumor etiology.
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MEC of the salivary glands with similar histological features.
Second, most of this tumor also shows carcinoma in situ
changes in the mucosa adjacent to the tumors. These features
suggest that this tumor arises from metaplastic changes in
squamous epithelium.12,13
The clinical features of esophageal MEC are basically
identical to those of SCC, with the major presenting symp-
toms of progressive dysphagia, retrosternal pain, and loss of
body weight. Thus, the diagnosis of this disease is depended
on histopathologic examination.8 Esophagoscopic biopsy is
the most frequently used method for the diagnosis before
treatment. But as the volume of the biopsy specimen is small,
this method gives a poor diagnostic result.8 Ozawa et al.11
reported two cases of esophageal MEC misdiagnosed as SCC
at esophagoscopic biopsy. In our study, 20 patients under-
FIGURE 1. Mucoepidermoid carcinoma of the esophagus, dif-
fuse infiltrated muscularis. Hematoxylin and eosin stain, 200.
FIGURE 2. Survival curve for the 36 patients with primary
esophageal mucoepidermoid carcinoma.
TABLE 2. Comparison of pTNM Stage Between Patients
with Esophageal MEC and SCC
pTNM Stage
No. of Patients
MEC SCC
Ia 1 126
Ib 0 179
IIa 0 653
IIb 23 1063
IIIa 6 950
IIIb 2 405
IIIc 4 611
IV 0 36
Total 36 4023
MEC, mucoepidermoid carcinoma; SCC, squamous cell carcinoma; TNM, tumor
node metastasis.
FIGURE 3. Survival curves for patients with and without
lymph node metastasis.
FIGURE 4. Survival curves for the patients who underwent
radical and palliative operation.
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went esophagoscopic biopsy. Eighteen cases were misdiag-
nosed as SCC, and the other two were misdiagnosed as
adenosquamous carcinoma. To diagnose MEC accurately at
preoperative esophagoscopic biopsy, more tissue should be
taken and a multipoint biopsy should be performed under an
endoscope. Moreover, alcian blue and/or mucicarmine staining
of the endoscopic biopsy specimen should also be performed if
the tumor contains both glandular carcinoma and SCC.11
For patients with esophageal MEC, surgical resection is
the primary treatment.3,8,11 Surgical treatment provides better
palliation and a reasonable survival time and is preferred for
patients with resectable disease who are physiologically fit
enough to undergo surgery.8 It has been reported that MEC
has a lower sensitivity to chemotherapy and radiotherapy than
SCC. Lieberman et al.14 reported that only 2 of 14 cases
survived more than 2 years after surgery followed by adju-
vant chemoradiotherapy. Hagiwara et al.1 reported five cases
of esophageal MEC who underwent preoperative chemother-
apy or radiotherapy, but the treatment had little effect in
endoscopic and esophagographic assessments, suggesting
that neither radiotherapy nor chemotherapy may be effective
for MEC. In our study, the MST did not show a statistically
significant difference between patients with and without ad-
juvant radiotherapy (p  0.172). It seems that adjuvant
TABLE 3. Univariate Analysis of the Prognosis of the 36 Patients with Primary Esophageal MEC
No. of Patients
Survival Rate (%)
MST, mo (95% CI) p1 yr 2 yr 3 yr 5 yr
Gender 0.647
Male 27 84.0 56.0 34.8 27.3 26.0 (16.2–35.8)
Female 9 88.9 75.0 42.3 28.6 59.0 (24.5–93.5)
Age (yr) 0.883
60 21 85.0 60.0 33.3 28.4 29.0 (22.5–35.5)
60 15 85.7 61.5 41.7 25.0 29.0 (1.8–56.2)
Location 0.467
Ut 5 100.0 50.0 50.0 50.0 23.0
Mt 28 81.5 65.4 34.8 27.3 29.0 (20.8–37.2)
Lt 3 100.0 33.3 33.3 0.0 20.0 (13.6–26.4)
Length 0.475
5 cm 27 84.6 68.0 40.9 28.6 29.0 (5.3–52.7)
5 cm 9 87.5 37.5 25.0 25.0 23.0 (16.7–29.3)
Macroscopic tumor type 0.267
Medullary 27 80.8 60.0 39.1 31.8 29.0 (21.8–36.2)
Intraluminal 1 100.0 0.0 0.0 0.0 16.0
Mushroom 1 100.0 0.0 0.0 0.0 14.0
Ulcerative 2 100.0 100.0 0.0 0.0 33.0
Sclerotic 5 100.0 80.0 50.0 35.0 59.0 (12.2–105.8)
pT 0.767
pT1  pT2 3 100.0 100.0 0.0 0.0 26.0
pT3  pT4 33 84.4 58.1 37.9 32.0 29.0 (19.7–38.3)
pN 0.003
pN0 28 88.5 72.0 47.8 36.4 48.0 (6.9–89.1)
pN1–3 8 75.0 25.0 0.0 0.0 16.0 (9.1–22.9)
Tumor cell differentiation 0.437
Well 7 85.7 71.4 50.0 50.0 —
Moderate 24 87.0 59.1 38.1 25.0 29.0 (18.0–40.0)
Poor 5 75.0 50.0 0.0 0.0 14.0 (0.0–33.6)
pTNM stage 0.128
I  II 24 86.4 76.2 44.4 29.4 48.0 (14.8–81.2)
III 12 83.3 33.3 25.0 25.0 20.0 (14.3–25.7)
Radiotherapy 0.172
No 26 84.0 60.0 33.3 21.7 29.0 (23.2–34.8)
Yes 10 88.9 62.5 50.0 50.0
Operation 0.006
Radical 32 90.0 69.0 42.3 32.0 33.0 (12.0–54.0)
Palliative 4 50.0 0.0 0.0 0.0 11.0 (1.2–20.8)
MEC, mucoepidermoid carcinoma; MST, median survival time; TNM, tumor node metastasis; Ut, upper third of thoracic esophagus; Mt, middle third of thoracic esophagus;
Lt, lower third of thoracic esophagus; CI, confidence interval.
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radiotherapy has little effect on esophageal MEC. However,
Turkyilmaz et al.8 considered that radiotherapy might offer
palliation of dysphagia in patients with advanced disease, and
adjuvant chemotherapy and radiotherapy might prolong sur-
vival in some patients with esophageal MEC. Recently,
neoadjuvant chemoradiation had been increasingly used for
the treatment of esophageal cancer patients15 and shown a
significant survival benefit.16 We think that further research
should be conducted to establish the value of this new
therapeutic method for MEC patients.
As for the prognosis of primary esophageal MEC, most
previous reports suggested that MEC was more aggressive
than SCC and suffered a higher risk of recurrence and
death.1–3,8 Hagiwara et al.1 reported eight cases of esophageal
MEC of whom four died of widespread metastases and two
died of local recurrence within 2 years after surgery. In the
report by Hagiwara et al.,1 the overall median survival time
was 10.8 months for esophageal MEC and 32.1 months for
ESCC (p  0.05). Koide et al.3 reviewed 22 cases of esoph-
ageal MEC who underwent surgical resection before 1998 in
Japan, and the 5-year survival rate was only 27.7%. Most of
them died of local recurrence or distant metastasis. In our
study, the 5-year survival rate for MEC patients was only
25.8%, which is lower than the 5-year absolute survival rate
of 39.2% (912/2328) for SCC patients. In addition, for pa-
tients who underwent a radical operation, the 5-year survival
rate of 32.0% for MEC patients was also lower than that of
41.7% (908/2175) for SCC patients. The poor prognosis of
esophageal MEC patients may be caused by its clinicopath-
ological aggressive behavior.1,3
In summary, primary MEC of the esophagus is a rare
disease and prone to be misdiagnosed by endoscopic biopsy.
Lymph node metastasis and operation type (radical/palliative)
are independent prognostic factors, and adjuvant radiotherapy
has little effect. Surgical resection is the primary treatment,
but the prognosis is poor. It is necessary to achieve further
improvements in the clinical outcome of patients with such
tumors by developing new therapeutic modalities.
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